Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
COSMOS PharmaceuticalCSMYF 89 Revenue per Share is $90.14 as of Feb. 2026. GuruFocus rates CSMYF with a GF Score™ of 89/100 and a GF Value™ of $51.94 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 612 Healthcare Providers & Services companies, COSMOS Pharmaceutical ranks better than 60.46% on this metric.
COSMOS Pharmaceutical's revenue per share for the
three
months ended in Feb. 2026 was $22.23.
COSMOS Pharmaceutical's revenue per share for the trailing twelve months (TTM) ended in Feb. 2026 was $90.14.
Good Sign:
COSMOS Pharmaceutical Corp has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue Per Share Growth Rate of COSMOS Pharmaceutical was 8.70% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 9.90% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 9.30% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 9.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for COSMOS Pharmaceutical's Revenue per Share or its related term are showing as below:
CSMYF'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -7.8 Med: 10.8 Max: 18.1
Current: 9.9
During the past 13 years, COSMOS Pharmaceutical's highest 3-Year average Revenue Per Share Growth Rate was 18.10% per year. The lowest was -7.80% per year. And the median was 10.80% per year.
CSMYF's 3-Year Revenue Growth Rate is ranked better than 60.46% of 612
companies
in the Healthcare Providers & Services industry
Industry Median: 6.9
vs CSMYF: 9.90
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
COSMOS Pharmaceutical Revenue per Share Related Terms
COSMOS Pharmaceutical Revenue per Share Historical Data
* Premium members only.
The historical data trend for COSMOS Pharmaceutical's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COSMOS Pharmaceutical Revenue per Share Competitor Comparison
For the Pharmaceutical Retailers subindustry, COSMOS Pharmaceutical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
COSMOS Pharmaceutical PS Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, COSMOS Pharmaceutical's PS Ratio distribution charts can be found below:
* The bar in red indicates where COSMOS Pharmaceutical's PS Ratio falls into.
COSMOS Pharmaceutical Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
COSMOS Pharmaceutical's Revenue Per Share for the fiscal year that ended in May. 2026 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $90.14
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COSMOS Pharmaceutical (CSMYF) has a Revenue per Share of $90.14 as of Feb. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on COSMOS Pharmaceutical and its competitors. According to the industry distribution chart, COSMOS Pharmaceutical ranks #242 out of 612 companies in the Healthcare Providers & Services industry, placing it in the top 39.5%.
Is COSMOS Pharmaceutical's Revenue per Share too high?
COSMOS Pharmaceutical's current Revenue per Share is $90.14. The Healthcare Providers & Services industry median Revenue per Share is 6.90. COSMOS Pharmaceutical's value of $90.14 is 1206.4% above this industry median. Based on the distribution chart, COSMOS Pharmaceutical ranks #242 out of 612 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, COSMOS Pharmaceutical has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does COSMOS Pharmaceutical's Revenue per Share compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, COSMOS Pharmaceutical ranks #242 out of 612 companies for Revenue per Share. This puts COSMOS Pharmaceutical in the upper half of its industry. The industry median Revenue per Share is 6.90. COSMOS Pharmaceutical's value of $90.14 is 1206.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Healthcare Providers & Services company?
The median Revenue per Share among Healthcare Providers & Services companies is 6.90, based on 612 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. COSMOS Pharmaceutical's current Revenue per Share of $90.14 is 1206.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on COSMOS Pharmaceutical and its competitors. For the Healthcare Providers & Services industry, the median Revenue per Share is 6.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. COSMOS Pharmaceutical's current Revenue per Share is $90.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is COSMOS Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, COSMOS Pharmaceutical (CSMYF) is currently considered Modestly Undervalued. The stock's GF Value™ is $51.94, compared to a current price of $37.06 — trading 28.6% below its estimated fair value. The current Revenue per Share is $90.14 and 1206.4% above the Healthcare Providers & Services industry median of 6.90. COSMOS Pharmaceutical's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For COSMOS Pharmaceutical (CSMYF), the current Revenue per Share is $90.14 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is COSMOS Pharmaceutical (CSMYF) Overvalued in 2026?
Based on GuruFocus' analysis, COSMOS Pharmaceutical stock appears to be undervalued.
The current stock price of $37.06 is trading 28.6% below its estimated GF Value™ of $51.94.
GuruFocus considers COSMOS Pharmaceutical to be Modestly Undervalued.
Key valuation signals for CSMYF:
Revenue per Share: $90.14
GF Value™: $51.94 vs. price of $37.06 (28.6% below fair value)
Industry Position: 1206.4% above the Healthcare Providers & Services median (#242 of 612)
No single metric tells the full story. See the CSMYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company emphasizes convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company's revenue is derived from common grocery sales. It also operates a private grocery brand called ON 365.
89GF Score
Get the complete analysis for CSMYF
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSMYF has been successfully added to your 
